小瓢虫传媒

The main objective of the MacroTwin project is to establish a scaled iPSC-macrophage manufacturing platform and create a Digital Twin thereof for use in allogeneic cell therapy product development and clinical trials. The project is based on a collaboration between Celyntra Therapeutics (d/b/a Cellistic), a cell therapy CDMO service provider with unique expertise in iPSC biology, immunology, and bioprocess development, Pharmalex, a leader in statistics, data science and analytics services for biopharmaceutical and medical product development, and the Institute of Condensed Matter and Nanosciences of UCLouvain (IMCN/BSMA) which introduces expertise on biomaterials necessary for bioprocess development. IMCN/BSMA is notably in charge of the development of a responsive coating allowing both in-process cell adhesion and easy 鈥渙n-demand鈥� recovery cells at the end of the process.